ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AMRI acquires U.K.’s Excelsyn

by Michael McCoy
February 22, 2010 | APPEARED IN VOLUME 88, ISSUE 8

Contract research organization AMRI has acquired Excelsyn, a U.K. pharmaceutical chemical manufacturer, for about $19 million in cash. AMRI CEO Thomas E. D’Ambra says Excelsyn gives his firm a European manufacturing presence and will help increase its business with large European drug companies. Excelsyn, which specializes in process research and development chemistry, operates a plant in Holywell, North Wales. The company employs 60 people and had sales last year of $15 million. It was founded in 2004 by Ian Shott, a fine chemicals executive who previously held posts at firms such as Rhodia, Lonza, and Zeneca. Shott will work with AMRI in a consulting role.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment